Yissum, the technology transfer company of the Hebrew University of Jerusalem in Israel, has licensed a novel package of stem cell-related technologies to pharmaceutical and biotechnology company TheraCell.
TheraCell will now further develop and commercialise the technology to build advanced regenerative medicine procedures using stem cells, including spinal fusion.
The licensed technology includes a biologically compatible, oxygenated gel that improves bone regeneration and fusion of bone grafts. This technology will be used in conjunction with TheraCell's proprietary scaffold technology, to enhance the efficiency of spinal fusion procedures.
Other licensing agreements include deals for novel and efficient methods for purifying and manipulating stem cells derived from patients.
Yissum CEO Yehuda Yarmut said that the ability to ensure adequate oxygen levels for cells can help not only with bone healing and bone stem cells, but also holds great promise for other stem cells, as well as for the survival of engineered tissue and organ grafts.
TheraCell president and CEO Rich Grant said that with this technology the company expects to be able to deliver products that are highly attractive to patients, health care providers and insurance payors, because they will significantly improve outcomes of these costly spine fusion procedures and reduce hospitalisation periods, significantly lowering the cost of treatment.